The role of active surveillance of small renal masses

International Journal of Surgery

Volumn 36, Issue , 2016, Pages 518-524

  Volpe, Alessandro ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

Active surveillance; Carcinoma; Natural history; Observation; Renal cell; Small renal mass

Indexed keywords

CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER MORTALITY; CANCER SURGERY; GROWTH RATE; HUMAN; KIDNEY TUMOR; METASTASIS; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; TUMOR VOLUME; CARCINOMA, RENAL CELL; DIAGNOSTIC IMAGING; DISEASE COURSE; KIDNEY NEOPLASMS; PATHOLOGY; WATCHFUL WAITING;

CARCINOMA, RENAL CELL; DISEASE PROGRESSION; HUMANS; KIDNEY NEOPLASMS; TUMOR BURDEN; WATCHFUL WAITING;

EID: 85008240168     PISSN: 17439191     EISSN: 17439159     Source Type: Journal    
DOI: 10.1016/j.ijsu.2016.06.007     Document Type: Review

References (56)

1. [1] Znaor, A., Lortet-Tieulent, J., Laversanne, M., Jemal, A., Bray, F., International variations and trends in renal cell carcinoma incidence and mortality. Eur. Urol. 67 (2015), 519–530.
2. [2] Kane, C.J., Mallin, K., Ritchey, J., Cooperberg, M.R., Carroll, P.R., Renal cell cancer stage migration: analysis of the national cancer data base. Cancer 113 (2008), 78–83.
3. [3] Patard, J.J., Rodriguez, A., Rioux-Leclercq, N., Guille, F., Lobel, B., Prognostic significance of the mode of detection in renal tumours. BJU Int. 90 (2002), 358–363.
4. [4] Frank, I., Blute, M.L., Cheville, J.C., Lohse, C.M., Weaver, A.L., Zincke, H., An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J. Urol. 168 (2002), 2395–2400.
5. [5] Tsui, K.H., Shvarts, O., Smith, R.B., Figlin, R., de Kernion, J.B., Belldegrun, A., Renal cell carcinoma: prognostic significance of incidentally detected tumors. J. Urol. 163 (2000), 426–430.
6. [6] Bell, E.T., A classification of renal tumors with observations on the frequency of the various types. J. Urol., 39, 1938, 238.
7. [7] Bosniak, M.A., Observation of small incidentally detected renal masses. Semin. Urol. Oncol. 13 (1995), 267–272.
8. [8] Volpe, A., Panzarella, T., Rendon, R.A., Haider, M.A., Kondylis, F.I., Jewett, M.A., The natural history of incidentally detected small renal masses. Cancer 100 (2004), 738–745.
9. [9] Kassouf, W., Aprikian, A.G., Laplante, M., Tanguay, S., Natural history of renal masses followed expectantly. J. Urol. 171 (2004), 111–113 discussion 3.
10. [10] Kato, M., Suzuki, T., Suzuki, Y., Terasawa, Y., Sasano, H., Arai, Y., Natural history of small renal cell carcinoma: evaluation of growth rate, histological grade, cell proliferation and apoptosis. J. Urol. 172 (2004), 863–866.
11. [11] Wehle, M.J., Thiel, D.D., Petrou, S.P., Young, P.R., Frank, I., Karsteadt, N., Conservative management of incidental contrast-enhancing renal masses as safe alternative to invasive therapy. Urology 64 (2004), 49–52.
12. [12] Kouba, E., Smith, A., McRackan, D., Wallen, E.M., Pruthi, R.S., Watchful waiting for solid renal masses: insight into the natural history and results of delayed intervention. J. Urol. 177 (2007), 466–470 discussion 70.
13. [13] Abouassaly, R., Lane, B.R., Novick, A.C., Active surveillance of renal masses in elderly patients. J. Urol. 180 (2008), 505–508 discussion 8–9.
14. [14] Crispen, P.L., Viterbo, R., Boorjian, S.A., Greenberg, R.E., Chen, D.Y., Uzzo, R.G., Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer 115 (2009), 2844–2852.
15. [15] Rosales, J.C., Haramis, G., Moreno, J., et al. Active surveillance for renal cortical neoplasms. J. Urol. 183 (2010), 1698–1702.
16. [16] Haramis, G., Mues, A.C., Rosales, J.C., et al. Natural history of renal cortical neoplasms during active surveillance with follow-up longer than 5 years. Urology 77 (2011), 787–791.
17. [17] Smaldone, M.C., Kutikov, A., Egleston, B.L., et al. Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer 118 (2012), 997–1006.
18. [18] Jewett, M.A., Mattar, K., Basiuk, J., et al. Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur. Urol. 60 (2011), 39–44.
19. [19] Mason, R.J., Abdolell, M., Trottier, G., et al. Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillance. Eur. Urol. 59 (2011), 863–867.
20. [20] Schiavina, R., Borghesi, M., Dababneh, H., et al. Small renal masses managed with active surveillance: predictors of tumor growth rate after long-term follow-up. Clin. Genitourin. Cancer 13 (2015), e87–92.
21. [21] Bahouth, Z., Halachmi, S., Meyer, G., Avitan, O., Moskovitz, B., Nativ, O., The natural history and predictors for intervention in patients with small renal mass undergoing active surveillance. Adv. Urol., 2015, 2015, 692014.
22. [22] Dorin, R., Jackson, M., Cusano, A., et al. Active surveillance of renal masses: an analysis of growth kinetics and clinical outcomes stratified by radiological characteristics at diagnosis. Int. Braz. J. Urol. 40 (2014), 627–636.
23. [23] Pierorazio, P.M., Johnson, M.H., Ball, M.W., et al. Five-year analysis of a multi-institutional prospective clinical trial of delayed intervention and surveillance for small renal masses: the DISSRM registry. Eur. Urol. 68:3 (2015 Sep), 408–415.
24. [24] Chawla, S.N., Crispen, P.L., Hanlon, A.L., Greenberg, R.E., Chen, D.Y., Uzzo, R.G., The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J. Urol. 175 (2006), 425–431.
25. [25] Organ, M., Jewett, M., Basiuk, J., et al. Growth kinetics of small renal masses: a prospective analysis from the Renal Cell Carcinoma Consortium of Canada. Can. Urol. Assoc. J. 8 (2014), 24–27.
26. [26] Danzig, M.R., Chang, P., Wagner, A.A., Pierorazio, P.M., Allaf, M.E., McKiernan, J.M., Active surveillance is superior to radical nephrectomy and equivalent to partial nephrectomy in preserving renal function among patients with small renal masses; results from the DISSRM registry. J. Urol. 194:4 (2015 Oct), 903–909.
27. [27] Lamb, G.W., Bromwich, E.J., Vasey, P., Aitchison, M., Management of renal masses in patients medically unsuitable for nephrectomy–natural history, complications, and outcome. Urology 64 (2004), 909–913.
28. [28] Mues, A.C., Haramis, G., Badani, K., et al. Active surveillance for larger (cT1bN0M0 and cT2N0M0) renal cortical neoplasms. Urology 76 (2010), 620–623.
29. [29] Mehrazin, R., Smaldone, M.C., Egleston, B., et al. Is anatomic complexity associated with renal tumor growth kinetics under active surveillance?. Urol. Oncol., 33, 2015 167 e7–e12.
30. [30] Ljungberg, B., Bensalah, K., Canfield, S., et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur. Urol. 67 (2015), 913–924.
31. [31] Van Poppel, H., Da Pozzo, L., Albrecht, W., et al. A prospective randomized EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur. Urol. 59:4 (2011 Apr), 543–552.
32. [32] Scosyrev, E., Messing, E.M., Sylvester, R., Campbell, S., Van Poppel, H., Renal function after nephron-sparing surgery versus radical nephrectomy: results from EORTC randomized trial 30904. Eur. Urol. 65 (2014), 372–377.
33. [33] Campbell, S.C., Novick, A.C., Belldegrun, A., et al. Guideline for management of the clinical T1 renal mass. J. Urol. 182 (2009), 1271–1279.
34. [34] Patard, J.J., Shvarts, O., Lam, J.S., et al. Safety and efficacy of partial nephrectomy for all T1 tumors based on an international multicenter experience. J. Urol. 171 (2004), 2181–2185 quiz 435.
35. [35] Liguori, G., Trombetta, C., Pomara, G., et al. Major invasive surgery for urologic cancer in octogenarians with comorbid medical conditions. Eur. Urol. 51 (2007), 1600–1604 discussion 5.
36. [36] Sun, M., Thuret, R., Abdollah, F., et al. Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur. Urol. 59 (2011), 135–141.
37. [37] Hellsten, S., Johnsen, J., Berge, T., Linell, F., Clinically unrecognized renal cell carcinoma. Diagnostic and pathological aspects. Eur. Urol. 18:Suppl. 2 (1990), 2–3.
38. [38] Hollingsworth, J.M., Miller, D.C., Daignault, S., Hollenbeck, B.K., Five-year survival after surgical treatment for kidney cancer: a population-based competing risk analysis. Cancer 109 (2007), 1763–1768.
39. [39] Arrontes, D.S., Acenero, M.J., Gonzales, J.I., Munoz, M.M., Andres, P.P., Survival analysis of clear cell renal carcinoma according to the Charlson comorbidity index. J. Urol. 179 (2008), 857–861.
40. [40] Lane, B.R., Abouassaly, R., Gao, T., et al. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer 116 (2010), 3119–3126.
41. [41] Patel, N., Cranston, D., Akhtar, M.Z., et al. Active surveillance of small renal masses offers short-term oncological efficacy equivalent to radical and partial nephrectomy. BJU Int. 110 (2012), 1270–1275.
42. [42] Zini, L., Perrotte, P., Jeldres, C., et al. A population-based comparison of survival after nephrectomy vs nonsurgical management for small renal masses. BJU Int. 103 (2009), 899–904 discussion.
43. [43] Sun, M., Bianchi, M., Trinh, Q.D., et al. Comparison of partial vs radical nephrectomy with regard to other-cause mortality in T1 renal cell carcinoma among patients aged ≥75 years with multiple comorbidities. BJU Int. 111:1 (2012 May 22), 67–73.
44. [44] Sun, M., Becker, A., Tian, Z., et al. Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. Eur. Urol. 65 (2014), 235–241.
45. [45] Berger, D.A., Megwalu, I.I., Vlahiotis, A., et al. Impact of comorbidity on overall survival in patients surgically treated for renal cell carcinoma. Urology 72 (2008), 359–363.
46. [46] Kutikov, A., Egleston, B.L., Wong, Y.N., Uzzo, R.G., Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram. J. Clin. Oncol. 28 (2010), 311–317.
47. [47] Lughezzani, G., Sun, M., Budaus, L., Thuret, R., Perrotte, P., Karakiewicz, P.I., Population-based external validation of a competing-risks nomogram for patients with localized renal cell carcinoma. J. Clin. Oncol. 28 (2010), e299–300 author reply e1.
48. [48] Volpe, A., Cadeddu, J.A., Cestari, A., et al. Contemporary management of small renal masses. Eur. Urol. 60 (2011), 501–515.
49. [49] Bhan, S.N., Pautler, S.E., Shayegan, B., Voss, M.D., Goeree, R.A., You, J.J., Active surveillance, radiofrequency ablation, or cryoablation for the nonsurgical management of a small renal mass: a cost-utility analysis. Ann. Surg. Oncol. 20 (2013), 3675–3684.
50. [50] Volpe, A., Jewett, M.A., The role of surveillance for small renal masses. Nat. Clin. Pract. Urol. 4 (2007), 2–3.
51. [51] Kunkle, D.A., Chen, D.Y., Greenberg, R.E., Viterbo, R., Uzzo, R.G., Metastatic progression of enhancing renal masses under active surveillance is associated with rapid interval growth of the primary tumor. J. Urol., 179(Suppl. 4), April 2008, 375.
52. [52] Zhang, L., Yin, W., Yao, L., et al. Growth pattern of clear cell renal cell carcinoma in patients with delayed surgical intervention: fast growth rate correlates with high grade and may result in poor prognosis. Biomed. Res. Int., 2015, 2015, 598134.
53. [53] Crispen, P.L., Viterbo, R., Fox, E.B., Greenberg, R.E., Chen, D.Y., Uzzo, R.G., Delayed intervention of sporadic renal masses undergoing active surveillance. Cancer 112 (2008), 1051–1057.
54. [54] Volpe, A., Finelli, A., Gill, I.S., et al. Rationale for percutaneous biopsy and histologic characterisation of renal tumours. Eur. Urol. 62 (2012), 491–504.
55. [55] Bosniak, M.A., Birnbaum, B.A., Krinsky, G.A., Waisman, J., Small renal parenchymal neoplasms: further observations on growth. Radiology 197 (1995), 589–597.
56. [56] Abou Youssif, T., Kassouf, W., Steinberg, J., Aprikian, A.G., Laplante, M.P., Tanguay, S., Active surveillance for selected patients with renal masses: updated results with long-term follow-up. Cancer 110 (2007), 1010–1014.